ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
Oct 12, 2022 10:00 JST
Source:
Novotech Health Holdings Pte Ltd
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority
SYDNEY, AU, Oct 12, 2022 - (ACN Newswire) - Novotech, the leading Asia Pacific biotech specialist CRO, has again received "Best Workplace" certification by the leading workplace culture organization Great Place to Work Institute. Novotech's India team has received a Best Workplaces for Women 2022 recognition and listed in the Top 75 organisations in India recognised for excelling people practices, responsiveness to feedback and a culture of openness and diversity. Novotech also holds Great Place to Workplace recognition in Australia and Korea.
To identify India's Best Workplaces for Women 2022, Great Place to Work India studied 1122 organizations that had:
- Women employees constituting at least 10% of their workforce
- Women employees sharing at least 70% positive feedback on the Great Place to Work Trust Index Organizations that excelled in gender parity in representation
According to Great Place to Work India: "We have observed that the Best Workplaces have gone above and beyond to create and sustain aspirational organizations. We congratulate Novotech for being a role-model in India by fostering an equal and equitable workplace culture."
Novotech CEO Dr. John Moller said: "As a leading employer of women in India we are extremely pleased to be ranked among the top companies in India as a Best Workplaces for Women 2022. This is especially important for retaining and attracting top talent. This recognition demonstrates the importance of culture, diversity and work life balance as we strive to be one of the leading employers so we can deliver our world-class CRO services across India."
Novotech's Chief People Officer Angela Edwardson said: "We are delighted that Novotech India has been recognized as a leading employer for women. This is a real credit to our workplace culture and leadership that drives all our Asia Pacific and North American teams. Novotech attracts a high proportion of talented female employees, so we are extremely proud to have our workplace recognized using the criteria from the Great Place to Work Institute's Trust Index and the Gender Parity in Experience & Representation. Our continued focus on building a leading workplace means team members can balance their personal responsibilities with work during all stages of life."
According to Yooni Kim, Vice President, Global Clinical Services Novotech: "Employees are the most valuable assets of a company. Novotech is dedicated to improving our working environment and enhance employee health and wellbeing. We are more than grateful to receive this recognition."
Sridevi Gubbala, Manager Centralized Document Management Novotech said: "Novotech is a great place to work. It's wonderful to have flexibility at work because it helps me balance my work and personal life."
Vandana Jaising, Manager Project Support joined Novotech after an extended career break and said: "Women should consider coming back, even if it is has been a while. Before joining Novotech I took an eight-year career break, and now I'm glad Novotech had the confidence in me to say 'YES! You can do it!'"
Novotech has operations across Asia Pacific and the US offering a unique and unparalleled suite of CRO services for early to late phase biotech clinical research.
Novotech has recently been benchmarked as a top 10 CRO among the world's leading CROs, is a finalist in the prestigious Scrip awards, and has just been awarded the Gene & Cell Therapy Excellence Award. In Asia Pacific Novotech has more than 50 Leading Site Partnership agreements with major medical research institutions which delivers exclusive benefits for sponsors.
About Novotech
Novotech is the leading Asia-Pacific biotech specialist CRO. Novotech has integrated labs and phase I facilities and provides drug development consulting and clinical development services across all phases. It has been instrumental in the success of approximately 4,000 clinical trials across a broad range of therapeutic areas. Novotech is well-positioned to serve biopharma clients conducting clinical trials in Asia-Pacific and the US. For more information visit
https://novotech-cro.com/contact
Media Contact
David James
E:
communications@novotech-cro.com
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427
Source: Novotech Health Holdings Pte Ltd
Sectors: Daily News, BioTech, Healthcare & Pharm, Local Biz, Clinical Trials
Copyright ©2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Latest Release
SAKENOVA: 28-Year-Old Master Brewer Pioneers AI-Driven Sake Revolution, Achieving 40% Cost Reduction While Winning International Gold Medals
Dec 15, 2025 23:00 JST
NEC Provides Vehicle Management Equipment for Autonomous Driving at Tokyo International Airport
Dec 15, 2025 19:41 JST
NEC and AEROTHAI Elevate Air Traffic Safety with Advanced Time Sync Solutions from Adtran Oscilloquartz
Dec 15, 2025 19:04 JST
Olympus Triples Venture Capital Fund Investment to Strengthen MedTech Leadership
Dec 15, 2025 08:30 JST
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion
Dec 12, 2025 23:15 JST
Honda to Launch New Heritage Service Business
Dec 12, 2025 20:31 JST
Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz
Dec 12, 2025 19:59 JST
NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries
Dec 12, 2025 18:13 JST
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition
Dec 12, 2025 11:00 JST
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 11, 2025 19:41 JST
NEC Named to CDP's "A List" for Climate Change and Water Security for the Seventh Consecutive Year
Dec 11, 2025 19:00 JST
MHI Successfully Produces Hydrogen at Its Ammonia Cracking Pilot Plant Using Steam Heating
Dec 10, 2025 18:14 JST
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Dec 10, 2025 12:00 JST
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 09, 2025 18:51 JST
NEC Wins TIP MUST Silver Badge with Advanced Network Operating System for Open Optical Transponders
Dec 09, 2025 13:39 JST
MHI and Worley to Deliver Full-Scale Carbon Capture Facility for Heidelberg Materials UK's Padeswood Cement Works
Dec 08, 2025 17:00 JST
Honda Technical Support for Red Bull Powertrains in F1 Racing Concludes
Dec 08, 2025 16:34 JST
MHIET U.S. Subsidiary's Franklin Plant Celebrates 10th Anniversary
Dec 08, 2025 16:03 JST
Lexus World Premieres Lexus LFA Concept BEV Sports Car
Dec 05, 2025 19:13 JST
TOYOTA GAZOO Racing World Premieres GR GT & GR GT3
Dec 05, 2025 18:58 JST
More Latest Release >>
Related Release
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar
February 15 2023 09:00 JST
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific
February 10 2023 19:00 JST
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW
February 03 2023 13:00 JST
Novotech Acquires US-based Drug Development Consulting Firm, CBR International
January 12 2023 15:00 JST
Novotech Acquires European CRO, Strengthens Global Operations
January 12 2023 15:00 JST
Novotech is Gold Sponsor at Biotech Showcase 2023
December 20 2022 11:00 JST
Data Shows 50% of New Trials Have Sites in Asia Pacific
December 15 2022 10:00 JST
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials
December 06 2022 11:00 JST
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy
November 11 2022 17:00 JST
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper
October 25 2022 18:00 JST
More Press release >>